Table 3

Known-group validity of the MDASI-Immunotherapy EPT by ECOG PS at baseline and week 9

	Patients with ECOG PS available, n	MDASI-Immunotherapy EPT symptom severity score*				MDASI-Immunotherapy EPT interference score†
	Patients with ECOG PS available, n	ECOG PS=0, mean (SD)	ECOG PS≥1, mean (SD)	95% CI	Effect size	ECOG PS=0, mean (SD)	ECOG PS≥1, mean (SD)	95% CI	Effect size
Baseline	145	1.3 (2.0)	1.8 (1.5)	−1.40 to 0.50	−0.45	2.1 (3.2)	2.5 (2.2)	−2.5 to 1.6	−0.19
Week 9	84	0.5 (0.7)	1.7 (1.4)	−2.60 to 0.08	−0.96	0.8 (1.1)	2.7 (2.3)	−4.1 to 0.4	−0.82

*The average of the 13 core and seven immunotherapy-specific symptom items.
†The average of the six interference items.
ECOG, Eastern Cooperative Oncology Group; MDASI-Immunotherapy EPT, Immunotherapy for Early-Phase Trials module of the MD Anderson Symptom Inventory; PS, performance status.